Article Text

Download PDFPDF
Response to: Correspondence on "Testing different thresholds for patient global assessment in defining remission for rheumatoid arthritis: are the current ACR/EULAR Boolean criteria optimal?" by Boers
  1. Paul Studenic1,2,
  2. Daniel Aletaha2,
  3. Tanja A Stamm3,
  4. Maarten de Wit4,
  5. Diane Lacaille5,6,
  6. Josef S Smolen2,
  7. David Felson7
  1. 1 Department of Medicine (Solna), Division of Rheumatology, Karolinska Institutet, Stockholm, Sweden
  2. 2 Department of Internal Medicine 3, Division of Rheumatology, Medical University of Vienna, Vienna, Austria
  3. 3 Center for Medical Statistics, Informatics, and Intelligent Systems, Institute for Outcomes Research, Medical University of Vienna, Vienna, Austria
  4. 4 EULAR community of People with Arthritis/Rheumatism in Europe (PARE), Zürich, Switzerland
  5. 5 Department of Medicine, Division of Rheumatology, University of British Columbia, Vancouver, British Columbia, Canada
  6. 6 Arthritis Research Canada, Vancouver, British Columbia, Canada
  7. 7 Section of Rheumatology, Boston University School of Medicine, Boston, Massachusetts, USA
  1. Correspondence to Dr Paul Studenic, Department of Internal Medicine 3, Division of Rheumatology, Medical University of Vienna, Vienna, Austria; paul.studenic{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

We thank Dr Boers for the reflections1 on the results of our ACR/EULAR endorsed work on the revision of the remission criteria for rheumatoid arthritis (RA).2 The main aims of this collaborative project were to validate the previously provisionally endorsed index-based remission criteria3 using the Clinical Disease Activity Index (CDAI) and Simplified Disease Activity Index (SDAI) and to adapt the Boolean definition to identify a more harmonised group of patients in remission. Through this procedure the interdefinition heterogeneity could be reduced.

In our analyses on the revision of the ACR/EULAR Boolean remission criteria, we embraced the Patient Global Assessment (PtGA) instrument as a continuous scale from 0 to 100 mm Visual Analogue Scale (VAS), based on the format used in the original clinical trial data underlying the …

View Full Text


  • Handling editor Kimme L Hyrich

  • Twitter @Stiddyo, @DanielAletaha

  • Contributors PS drafted the manuscript and all authors contributed, revised it and approved its final version.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests DA received research grants from Abbvie, Amgen, Lilly, Novartis, Roche, SoBi, Sanofim and consultancy/speaker fees from Abbvie, Amgen, Lilly, Janssen, Merck, Novartis, Pfizer, Roche, Sandoz; all outside the submitted work. MdW received over the last three years fees for lectures through Stichting Tools from Celgene, Eli Lilly, Pfizer and UCB. JSS Research Grants: Abbvie, AstraZeneca, Lilly, Novartis and Roche; honoraria for consultancies and/or speaking engagements: AbbVie, Amgen, AstraZeneca, Astro, Bristol-Myers Squibb, Celgene, Celltrion, Chugai, Evapharm, Gilead, ILTOO, Janssen, Lilly, Merck Sharp & Dohme, Novartis- Sandoz, Pfizer, R-Pharm, Roche, Samsung, Sanofi, and UCB. Editor Annals of the Rheumatic Diseases. TAS has received grant/research support from AbbVie and Roche, has been a consultant for AbbVie and Sanofi Genzyme, and has been a paid speaker for AbbVie, Roche, Sanofi and Takeda. PS received research grants from AbbVie and has been a paid speaker for Astra Zeneca.

  • Provenance and peer review Commissioned; internally peer reviewed.

Linked Articles